Asia Pacific Lung Cancer Therapy Market

The Asia Pacific lung cancer therapy market was valued at US$ 3,778.03 million in 2022 and is expected to reach US$ 10,963.26 million by 2030; it is estimated to grow at a CAGR of 14.2% from 2022 to 2030.

Increase in Cases of Lung Cancer Drive Asia Pacific Lung Cancer Therapy Market

Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020. As per the Cancer Australia 2023 report, ~14,529 new lung cancer cases were diagnosed in 2022; 7,707 were males and 6,822 were females. Nearly 9% of registered new cancer cases were diagnosed in 2022, with an estimated 8,664 deaths from lung cancer. Also, according to studies from the Indian Council of Medical (ICMR), the number of lung cancer cases in India is expected to increase by more than seven times by 2025 when compared to the same period a decade earlier. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.

Asia Pacific Lung Cancer Therapy Market Overview

China has experienced the increasing prevalence of lung cancer over the past few years owing to the various factors including smoking, tobacco consumption, and others. As per the International Agency for Research on Cancer reported that approximately 820,000 new lung cancer diagnoses and 715,000 lung cancer-related deaths occurred in China in 2020. A few of the primary causes of lung cancer in China include tobacco use, radiation exposure, family history, and the presence of chronic lung diseases. Further, image-guided percutaneous lung ablation has proven to be an effective alternative approach for the treatment of lung cancer and other lung malignancies.

Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Lung Cancer Therapy Market Segmentation

The Asia Pacific lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Asia Pacific lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Asia Pacific lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Asia Pacific lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Asia Pacific lung cancer therapy market is segmented into China, Japan, India, Australia, South Korea, Southeast Asia, and the Rest of Asia Pacific. China dominated the Asia Pacific lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Asia Pacific lung cancer therapy market.

Asia Pacific Lung Cancer Therapy Market Strategic Insights

Asia Pacific Lung Cancer Therapy Market Segmentation Analysis

Asia Pacific Lung Cancer Therapy Market Report Highlights

Asia Pacific Lung Cancer Therapy Report Scope

Asia Pacific Lung Cancer Therapy Market Country and Regional Insights